Search

Your search keyword '"SOMWAR, ROMEL"' showing total 490 results

Search Constraints

Start Over You searched for: Author "SOMWAR, ROMEL" Remove constraint Author: "SOMWAR, ROMEL"
490 results on '"SOMWAR, ROMEL"'

Search Results

2. Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

5. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification

6. Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

8. Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells

15. Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy

16. Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer

17. Resistance to TRK inhibition mediated by convergent MAPK pathway activation

19. HER4 and EGFR activate cell signaling in NRG1 fusion-driven cancers: implications for HER2/HER3-specific vs. pan-HER targeting strategies

23. Abstract 6127: MDM2 inhibition in combination with MEK inhibition in pre-clinical models of lung adenocarcinomas with MDM2 amplification

24. Supplementary Table from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

25. Abstract 4007: Efficacy of vepafestinib in preclinical models of RET fusion-driven sarcoma models

26. Supplementary Figure from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

27. Data from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

33. Data from Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers

34. Supplementary Figures from Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers

35. Supplementary Table from Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers

36. Supplementary Methods from Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers

48. Figure S1 from Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor

50. Supplementary Figure S3 from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions

Catalog

Books, media, physical & digital resources